Stegent Equity Advisors’s Genmab GMAB Stock Holding History

Stegent Equity Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,255	Closed	-$223K	–	113
2025 Q4	$223K	Buy	+7,255	New	+$226K	0.17%	112

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Stegent Equity Advisors's GMAB Position: Q1 2026 in Review

Stegent Equity Advisors sold out of Genmab (GMAB) in Q1 2026, closing a stake of 7,255 shares — an estimated $223K sold.

Stegent Equity Advisors first reported a position in GMAB in Q4 2025 and held it in 1 quarter. The position peaked at $223K in Q4 2025. 275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Stegent Equity Advisors reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
Stegent Equity Advisors sold 7,255 Genmab shares in Q1 2026, an estimated $223K.
Stegent Equity Advisors first reported a position in Genmab in Q4 2025 and held it in 1 quarter.
Stegent Equity Advisors's Genmab position peaked at $223K in Q4 2025.
275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Stegent Equity Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.